Literature DB >> 23474367

15-lipoxygenase-1/15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B and heat shock protein 90 complex activation.

Jun Ma1, Lei Zhang, Jianguo Zhang, Mengmeng Liu, Liuping Wei, Tingting Shen, Cui Ma, Yanyan Wang, Yingli Chen, Daling Zhu.   

Abstract

Hepatocellular carcinoma is a typical hypervascular tumor resulted from excessive growth of tumor cells. Previous studies have demonstrated that the lipoxygenase is considered as a potential therapeutic target and have important influence on human cancers. However, whether the 15-lipoxygenase-1 (15-LO-1)/15-hydroxyeicosatetraenoic acid (15-HETE) pathway participates in the development and progression of hepatocellular carcinoma has not been reported until now. To test the hypothesis that the 15-LO-1/15-HETE signaling regulates hepatocellular carcinoma cells growth and metastasis via the phosphoinositide-3 kinase (PI3K)/protein kinase B (Akt)/heat shock protein 90 pathway, we performed these studies. Our results showed that hepatocellular carcinoma cell lines (HepG2 and SMMC7721) apoptosis and growth arrest occurred following blockade of the 15-LO pathway with a 15-LO-1 inhibitor or siRNA, and all the effects were reversed by exogenous 15-HETE. Meanwhile, 15-HETE strengthened the expression of phosphor-Akt and heat shock protein 90, and inhibited apoptosis induced by serum deprivation via promoting the interaction of Akt with heat shock protein 90. In addition, the invasion and migration of HepG2 enhanced by 15-HETE were both attenuated by the inhibitor of Akt or heat shock protein 90. These results indicate that the 15-LO-1/15-HETE pathway prevents hepatocellular carcinoma cells from apoptosis and promotes hepatocellular carcinoma progression via a specific intracellular signaling pathway centered by the interaction of Akt with heat shock protein 90, and suggest a new therapeutic target for hepatocellular carcinoma.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474367     DOI: 10.1016/j.biocel.2013.02.018

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  8 in total

Review 1.  Emerging cellular functions of the lipid metabolizing enzyme 15-Lipoxygenase-1.

Authors:  Melis Çolakoğlu; Sinem Tunçer; Sreeparna Banerjee
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 6.831

2.  PKIB promotes cell proliferation and the invasion-metastasis cascade through the PI3K/Akt pathway in NSCLC cells.

Authors:  Penghui Dou; Danfeng Zhang; Zhuoxin Cheng; Gang Zhou; Linyou Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2016-06-20

Review 3.  Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.

Authors:  Daniella C N Hall; Ralf A Benndorf
Journal:  Cell Mol Life Sci       Date:  2022-07-02       Impact factor: 9.207

4.  Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.

Authors:  Asem I Fitian; David R Nelson; Chen Liu; Yiling Xu; Miguel Ararat; Roniel Cabrera
Journal:  Liver Int       Date:  2014-04-28       Impact factor: 5.828

5.  Key Role of ROS in the Process of 15-Lipoxygenase/15-Hydroxyeicosatetraenoiccid-Induced Pulmonary Vascular Remodeling in Hypoxia Pulmonary Hypertension.

Authors:  Qian Li; Min Mao; Yanli Qiu; Gaofeng Liu; Tingting Sheng; Xiufeng Yu; Shuang Wang; Daling Zhu
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

6.  Potential Anticancer Lipoxygenase Inhibitors from the Red Sea-Derived Brown Algae Sargassum cinereum: An In-Silico-Supported In-Vitro Study.

Authors:  Sami I Alzarea; Abeer H Elmaidomy; Hani Saber; Arafa Musa; Mohammad M Al-Sanea; Ehab M Mostafa; Omnia Magdy Hendawy; Khayrya A Youssif; Abdullah S Alanazi; Metab Alharbi; Ahmed M Sayed; Usama Ramadan Abdelmohsen
Journal:  Antibiotics (Basel)       Date:  2021-04-10

Review 7.  Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases.

Authors:  Akram Safaei; Afsaneh Arefi Oskouie; Seyed Reza Mohebbi; Mostafa Rezaei-Tavirani; Mohammad Mahboubi; Maryam Peyvandi; Farshad Okhovatian; Mona Zamanian-Azodi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016

8.  Differentiating between cancer and normal tissue samples using multi-hit combinations of genetic mutations.

Authors:  Sajal Dash; Nicholas A Kinney; Robin T Varghese; Harold R Garner; Wu-Chun Feng; Ramu Anandakrishnan
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.